Erickson JW - Search Results

1

Design, synthesis, and resistance patterns of MP-134 and MP-167, two novel inhibitors of HIV type 1 protease.

Mo H, Markowitz M, Majer P, Burt SK, Gulnik SV, Suvorov LI, Erickson JW, Ho DD. Mo H, et al. Among authors: erickson jw. AIDS Res Hum Retroviruses. 1996 Jan 1;12(1):55-61. doi: 10.1089/aid.1996.12.55. AIDS Res Hum Retroviruses. 1996. PMID: 8825619

2

Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor.

Markowitz M, Mo H, Kempf DJ, Norbeck DW, Bhat TN, Erickson JW, Ho DD. Markowitz M, et al. Among authors: erickson jw. J Virol. 1995 Feb;69(2):701-6. doi: 10.1128/JVI.69.2.701-706.1995. J Virol. 1995. PMID: 7815532 Free PMC article.

3

Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor.

Ho DD, Toyoshima T, Mo H, Kempf DJ, Norbeck D, Chen CM, Wideburg NE, Burt SK, Erickson JW, Singh MK. Ho DD, et al. Among authors: erickson jw. J Virol. 1994 Mar;68(3):2016-20. doi: 10.1128/JVI.68.3.2016-2020.1994. J Virol. 1994. PMID: 8107264 Free PMC article.

4

Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure.

Gulnik SV, Suvorov LI, Liu B, Yu B, Anderson B, Mitsuya H, Erickson JW. Gulnik SV, et al. Among authors: erickson jw. Biochemistry. 1995 Jul 25;34(29):9282-7. doi: 10.1021/bi00029a002. Biochemistry. 1995. PMID: 7626598

5

Flap opening in HIV-1 protease simulated by 'activated' molecular dynamics.

Collins JR, Burt SK, Erickson JW. Collins JR, et al. Among authors: erickson jw. Nat Struct Biol. 1995 Apr;2(4):334-8. doi: 10.1038/nsb0495-334. Nat Struct Biol. 1995. PMID: 7796268

6

Structural mechanisms of HIV drug resistance.

Erickson JW, Burt SK. Erickson JW, et al. Annu Rev Pharmacol Toxicol. 1996;36:545-71. doi: 10.1146/annurev.pa.36.040196.002553. Annu Rev Pharmacol Toxicol. 1996. PMID: 8725401 Review.

7

Structure-based design of achiral, nonpeptidic hydroxybenzamide as a novel P2/P2' replacement for the symmetry-based HIV protease inhibitors.

Randad RS, Lubkowska L, Silva AM, Guerin DM, Gulnik SV, Yu B, Erickson JW. Randad RS, et al. Among authors: erickson jw. Bioorg Med Chem. 1996 Sep;4(9):1471-80. doi: 10.1016/0968-0896(96)00140-x. Bioorg Med Chem. 1996. PMID: 8894104

8

Unsymmetric nonpeptidic HIV protease inhibitors containing anthranilamide as a P2' ligand.

Randad RS, Lubkowska L, Eissenstat MA, Gulnik SV, Yu B, Bhat TN, Clanton DJ, House T, Stinson SF, Erickson JW. Randad RS, et al. Among authors: erickson jw. Bioorg Med Chem Lett. 1998 Dec 15;8(24):3537-42. doi: 10.1016/s0960-894x(98)00657-x. Bioorg Med Chem Lett. 1998. PMID: 9934467

9

HIV protease: enzyme function and drug resistance.

Gulnik S, Erickson JW, Xie D. Gulnik S, et al. Among authors: erickson jw. Vitam Horm. 2000;58:213-56. doi: 10.1016/s0083-6729(00)58026-1. Vitam Horm. 2000. PMID: 10668400 Review.

10

Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies.

Erickson JW, Gulnik SV, Markowitz M. Erickson JW, et al. AIDS. 1999;13 Suppl A:S189-204. AIDS. 1999. PMID: 10885776 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

177 results

Search Page

Filters